New hope for rare leukemia: targeted pill shows promise in early trial
NCT ID NCT04409639
First seen Jun 27, 2026 · Last updated Jul 22, 2026 · Updated 2 times
Summary
This study tests a drug called cobimetinib in people with a rare blood cancer (CMML) that has certain gene mutations. The goal is to see if the drug can shrink or control the cancer. Fourteen adults with either new or treatment-resistant CMML will take the drug daily in 3-week-on, 1-week-off cycles. The main focus is how many patients respond, and safety is also tracked.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
-
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utah, 84112, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets genetic weakness in Hard-to-Treat blood cancers
- New transplant recipe targets tough leukemia
- Experimental drug for tough leukemias hits dead end
- New hope for tough blood cancers: first human trial launches
- New drug duo aims to tame rare bone marrow cancers
- Could a targeted drug make stem cell transplants more effective for tough blood cancers?